<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0066">HCV treatment uptake in Australia was initially high, but has begun to fall over the past 12 months 
 <xref rid="JVEv5-bib-0039" ref-type="bibr">[39]</xref>. Several barriers for linkage to care were identified, such as: a shortage of healthcare practitioners in some area (particularly rural and regional Australia), lack of coverage services; stigma and discrimination; accessing tertiary care services; and HCV being not a priority 
 <xref rid="JVEv5-bib-0018" ref-type="bibr">[18]</xref> (
 <xref rid="JVEv5-tbl-0001" ref-type="table">Table 1</xref>). As a solution, Australia redefined linkage to care models towards the community, where patient access to services and care was decentralised. Several studies, for example, the PRIME study and RAPID-EC, showed that patients were more likely to engage in care when DAAs were given in primary care compared to tertiary hospitals 
 <xref rid="JVEv5-bib-0019" ref-type="bibr">[19,40]</xref>. Prescribing rules were changed and, by 2018, most DAAs were prescribed by general practitioners.
</p>
